BMY News

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results.

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy.

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant overall survival benefits.

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a decision expected by June 2025.

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline.

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates.